LOC339047 Inhibitors

WZ4002 and Selumetinib are inhibitors that specifically target the EGFR and MEK enzymes, respectively, which are central components of the MAPK/ERK signaling pathway. By inhibiting these enzymes, these compounds can downregulate signaling cascades that may intersect with the function of LOC339047. Similarly, PF-04691502 and MK-2206 are inhibitors that target the PI3K/mTOR and AKT pathways, crucial for cell growth and survival, thus potentially influencing the functional context of LOC339047. Alisertib and ZM447439 function as inhibitors of Aurora kinases, which play critical roles in cell division. The inhibition of these kinases can affect proteins like LOC339047 if they are involved in or regulated by mitotic processes. Ibrutinib and Ruxolitinib, on the other hand, target Bruton's tyrosine kinase and JAK1/2, respectively, and are involved in signaling that controls hematopoiesis and immune responses. The inhibition of these kinases may affect LOC339047 if it is implicated in similar cellular responses.

Trametinib, another MEK inhibitor, and Sorafenib, a RAF inhibitor, can also impact the MAPK/ERK pathway. Their role in inhibiting key steps of this pathway can downregulate proteins that are regulated by or interact with components of this signaling cascade. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, can inhibit pathways involved in angiogenesis and cell proliferation, which may intersect with the biological processes involving LOC339047. Lastly, Thalidomide, a modulator of the cereblon E3 ligase, plays a role in protein homeostasis by affecting the degradation of certain proteins.